Filed by Harvard Bioscience, Inc.

                    Pursuant to Rule 425 under the Securities Act of 1933, as
                    amended, and deemed filed pursuant to Rule 14a-12 under the
                    Securities Exchange Act of 1934, as amended

                    Subject Company: Genomic Solutions Inc. Commission File No.:
                    000-30549

This filing contains statements about Harvard Bioscience, Inc. ("HBIO"), Genomic
Solutions Inc. ("GNSL") or the proposed combination of HBIO and GNSL that are
not statements of historical fact and are forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. These statements involve known and unknown
risks, uncertainties and other factors that may cause HBIO's and GNSL's actual
results, performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by the forward-looking
statements. Forward-looking statements include, but are not limited to
statements about the impact of an acquisition on future revenues and earnings,
the expected closing date of the transaction, HBIO's and GNSL's ability to
consolidate and leverage the business, acquired technology, sales force or
marketing expertise, the ability of GNSL to achieve HBIO's traditional growth
rates and HBIO's and GNSL's plans, objectives and intentions contained in this
press release that are not historical facts. In particular there is a risk that
the acquisition will not generate revenues or pro forma earnings that HBIO and
GNSL anticipate. Other factors that may cause HBIO's and GNSL's actual results
to differ materially from those in the forward looking statements include those
set forth under the heading "Important Factors That May Affect Future Operating
Results" in HBIO's Annual Report on Form 10-K for the fiscal year ended December
31, 2001 and under the heading "Risk Factors" in GNSL's Annual Report on Form
10-K for the fiscal year ended December 31, 2001, as well as other risks
described in HBIO's and GNSL's public filings or factors, if any, of which HBIO
and GNSL are not currently aware. HBIO and GNSL may not update these
forward-looking statements, even though their situation may change in the
future, unless they have obligations under the Federal securities laws to update
and disclose material developments related to previously disclosed information.

Harvard Bioscience, Inc. will be filing relevant documents concerning the merger
with the Securities and Exchange Commission including a registration statement
on Form S-4 containing a prospectus. WE URGE INVESTORS TO READ THESE DOCUMENTS
BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors will be able to obtain
these documents free of charge at the SEC's website, (http://www.sec.gov). In
addition, documents filed with the SEC by Harvard Bioscience, Inc. can be
obtained, without charge, by directing a request to Harvard Bioscience, Inc.,
Attn: Chief Financial Officer, telephone (508) 893-8999. Harvard Bioscience,
Inc. and its directors and executive officers may be deemed to be participants
in the solicitation of proxies in connection with the merger. Information about
the directors and executive officers of



Harvard Bioscience, Inc. and their ownership of Harvard Bioscience, Inc. common
stock is set forth in the proxy statement for Harvard Bioscience, Inc.'s 2002
annual meeting of stockholders as filed on Schedule 14A with the SEC on April
17, 2002. Additional information about the interests of those participants may
be obtained from reading the definitive prospectus regarding the proposed
transaction when it becomes available.

GNSL will file a proxy statement with the Securities and Exchange Commission in
connection with the proposed transaction. The proxy statement will be sent to
the stockholders of GNSL seeking their approval of the proposed transaction.
Investors and security holders are urged to read the proxy statement because it
will contain important information. When filed, this document may be obtained
free of charge at the website maintained by the Securities and Exchange
Commission at "www.sec.gov." This document may also be obtained free of charge
by requesting it in writing from Genomic Solutions Inc., Investor Relations,
4355 Varsity Drive, Ann Arbor, Michigan 48108. GNSL and its officers and
directors may be deemed to be participants in the solicitation of proxies from
GNSL stockholders in favor of the merger. A description of the interests of
GNSL's executive officers and directors in GNSL is set forth in the proxy
statement for GNSL's annual meeting of stockholders, which was filed with the
Securities and Exchange Commission on April 11, 2002.

THE FOLLOWING IS THE FORM OF A LETTER WITH AN ATTACHMENT SENT BY GNSL TO CERTAIN
OF ITS STOCKHOLDERS ON AUGUST 15, 2002:



[Genomic Solutions Letterhead]

August __, 2002

[mail merge address]

Dear Stockholder:


         As you are most likely aware, Genomic Solutions Inc. (the "Company")
has signed a merger agreement, pursuant to which the Company will be merged with
and into a subsidiary of Harvard Bioscience, Inc. ("Harvard"). A copy of the
joint press release announcing the merger agreement is enclosed with this
letter. You may obtain a copy of the merger agreement from the Securities and
Exchange Commission's website at WWW.SEC.GOV.

         You are receiving this letter because you are a party to [a
Stockholders Agreement dated December 24, 1997 (amended and restated as of
January 25, 2000)] [an Investor Agreement dated December 1997] [an Amended
Registration Rights Agreement dated April 23, 1999, as amended on October 28,
1999] by and among the Company and certain of its stockholders (the
"Agreement"). Under the Agreement you have certain registration rights with
respect to shares of the Company's common stock.

         In connection with the merger, Harvard is requiring us to obtain from
you the termination of all of your registration rights under the Agreement. At
the closing of the merger, in exchange for your shares of Company common stock,
you will receive cash and shares of Harvard common stock registered under the
Securities Act of 1933 ("Securities Act"), unless you properly exercise your
dissenters' rights under Delaware law. Your dissenters' rights will be more
fully described in the proxy statement and prospectus which will be filed with
the Securities and Exchange Commission in the near future. The Company urges you
to read the proxy statement and prospectus in its entirety. Unlike the
restricted shares of Company common stock that you now own, you will be able to
freely sell the shares of Harvard common stock received in the merger (with some
limited exceptions) without registration under the Securities Act as long as you
sell in a brokers' transaction. If you are deemed to be an affiliate of the
Company under the Securities Act, your ability to freely sell the Harvard shares
may be limited by Rule 145 promulgated under the Securities Act, which includes
a restriction on the number of securities you can sell at any one time. Except
under certain unusual circumstances, we do not believe this limitation should
apply to you. Please note that the agreement to terminate your registration
rights is conditioned upon the closing of the merger. That is, if the merger
does not close, the termination of your registration rights, by its terms, will
be null and void, and you will retain registration rights with respect to your
shares of Company common stock as if you had never signed the enclosed form.

         We urge you to sign and date the enclosed Termination of Registration
Rights form and return it to Lee Kellert at Jaffe, Raitt, Heuer & Weiss,
Professional Corporation, in the enclosed, self-addressed, stamped envelope, as
soon as possible so that it is received no later than August 23, 2002. You may
also fax your form to Lee at (313) 961-8358. Should you have any questions
regarding the form, or your registration rights in general, please contact Lee
at (313) 961-8380.

                                   Sincerely,


                               Jeffrey S. Williams



                       TERMINATION OF REGISTRATION RIGHTS

The undersigned (the "Stockholder") hereby acknowledges the following:

     A. The Stockholder is a holder of common stock of Genomic Solutions Inc., a
Delaware corporation (the "Company"), and is a party to [a Stockholders
Agreement dated December 24, 1997 (amended and restated as of January 25, 2000)]
[an Investor Agreement dated December 1997] [an Amended Registration Rights
Agreement dated April 23, 1999, as amended on October 28, 1999] by and among the
Company and certain of its stockholders (the "Agreement").

     B. The Stockholder holds rights under the Agreement(s) to cause the Company
to register under the Securities Act of 1933, as amended, shares of common stock
or other securities of the Company held by the Stockholder or as to which the
Stockholder has the right to acquire ("Registration Rights").

     C. The Company and Harvard Bioscience, Inc. ("Harvard") have entered into
an Agreement and Plan of Merger dated July 17, 2002 ("Merger Agreement"), under
which the Company is to be merged with and into a subsidiary of Harvard (the
"Merger").

     D. The Stockholder has received and has had the opportunity to review the
letter dated August 12, 2002 from Jeff Williams.

     E. The Stockholder will receive consideration in the Merger as a
stockholder of the Company.

     F. It is a condition to the Closing (as defined in the Merger Agreement)
that the Stockholder's Registration Rights be terminated.

         In consideration of the foregoing and for other good and adequate
consideration, the receipt and sufficiency of which the Stockholder hereby
acknowledges, the Stockholder agrees that, immediately before, and conditioned
upon, the Closing all Registration Rights shall be terminated, and such
Registration Rights shall have no further force or effect after the Closing.

PLEASE SIGN AND DATE THIS FORM AND RETURN IT TO JAFFE, RAITT, HEUER & WEISS,
PROFESSIONAL CORPORATION: ATTENTION: LEE KELLERT, IN THE ENCLOSED,
SELF-ADDRESSED, STAMPED ENVELOPE, AS SOON AS POSSIBLE SO THAT IT IS RECEIVED NO
LATER THAN AUGUST 23, 2002. YOU MAY ALSO FAX THIS FORM TO LEE AT (313) 961-8358

Dated: August ___, 2002                     STOCKHOLDER

                                                  __________________________

                                                 By: __________________________
                                                 Its: _________________________
Acknowledged and agreed:
GENOMIC SOLUTIONS INC.

By: ____________________________________
Its: ___________________________________